2024 PARTNERS
Roche
Lead Partner
With global headquarters located in Basel, Switzerland, Roche is a pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotechnology company and the world leader in vitro diagnostics and tissue-based cancer diagnostics. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche Diagnostics, a division of Roche, offers the industry’s most comprehensive in-vitro diagnostics solutions, covering molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, laboratory automation and IT and decision support solutions. With its products and services, Roche Diagnostics supports healthcare providers in transforming data into actionable insights.
Flagship Biosciences
Program Partner
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success.
PredxBio
Program Partner
PredxBio, headquartered in Pittsburgh, PA, is dedicated to developing explainable AI-driven spatial analytics software platforms. PredxBio platform aims to unravel the intricate complexities of cancer biology, thereby accelerating advancements in drug development and clinical trials. The company's solutions empower clinicians and researchers by facilitating efficient drug discovery, optimized clinical trials, advanced companion diagnostics, personalized therapeutic options, and enhanced clinical workflows. PredxBio has successfully established a strong pipeline of early customers, including pharmaceutical partners who leverage PredxBio solutions to investigate the reasons behind varying responses to therapy among patients in their clinical trials. The company's customers already recognize the immense value of PredxBio solutions, which can seamlessly scale from early discovery to clinical research.
Enable Medicine
Program Partner
Built by scientists, for scientists, Enable is the most comprehensive solution for your advanced biological research needs. Partner with our in-house experts to supercharge your data-to-insights R&D funnel and address targeted biological questions. Alongside hands-on support from the Enable team, take advantage of the Enable Cloud Platform, which integrates powerful visualization and analysis tools, high-parameter data storage, and extensive index and search capabilities, to fuel seamless data management, accelerated discovery, and team collaboration.
Aspect Analytics
Meeting Partner
At Aspect Analytics, our mission is to empower scientific discovery through pioneering bioinformatics solutions. We seek to advance our understanding of biology by leveraging advanced machine learning, cloud computing, and modern software development. Our goal is to drive the future of life sciences research by enabling our partners to make the most of their omics data.
Nucleai
Program Partner
Nucleai is the leading AI-powered spatial biomarker company, driving innovation at the intersection of technology and healthcare. Leveraging military intelligence-grade geospatial
analytical methods, it intercepts, interprets, and analyzes complex cellular conversations and spatially oriented interactions within tissue samples, translating them into actionable insights. Nucleai’s platform empowers pathologists and researchers with an AI-powered data-rich action plan, paving the way for more informed decisions in the development of bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. Nucleai’s investors include Section 32, Sanofi, Vertex Ventures, M Ventures, and Debioopharm. It is headquartered in Israel and Chicago.
Ultivue
Meeting Partner
Ultivue seeks to give every patient the best chance of a cure by revealing the true state of cancer using spatial phenomics. Imagine a partner that supports your biomarker journey through the entire development pipeline, from the beginning, with defining and framing your specific scientific question, developing your biomarker panel, all the way through to delivering answers that enable your project to move forward and make an impact in personalized medicine.
Panakeai
Program Partner
Panakeia provides comprehensive ‘omics' molecular analysis of patient tissues significantly faster and cheaper than other methods. We are creating AI technology to provide biomarker information directly from H&E-stained tissue images. Panakeia offers reliable results in minutes rather than executing multiple physical tests over several days or weeks. Our offerings enhance both clinical diagnostics and drug development.